Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2023 on request of the Sponsor.
On 26 March 2014, orphan designation (EU/3/14/1258) was granted by the European Commission to Eudax Srl, Italy, for doxorubicin(6-maleimidocaproyl)hydrazone for the treatment of soft tissue sarcoma.
Treatment of soft tissue sarcoma
|Orphan designation status||
|EU designation number||
|Date of designation||
|May 2023||The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.|
|March 2015||The sponsorship was transferred to Pharma Gateway AB, Sweden.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: